Lysogene Announces the Conversion of the Reorganization Proceedings into Judicial Liquidation and its Delisting
Paris, France — 25 May 2023 at 06:00 pm CET — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that the Commercial Court of Nanterre has decided to convert the reorganization proceedings of the Company, opened by judgment on January 24, 2023, into liquidation proceedings. As…